Camel-IDS is a biotech company developing targeted radionuclide therapeutic solutions against cancer. Camel-IDS was incorporated on October 14th 2014 in Brussels, Belgium to leverage a technology platform that has been developed at VUB (Vrije Universiteit Brussel). Camel-IDS is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (Camelids), coupled with a therapeutic radioisotope. Camelids are used to transport the radioisotope to selected cancer receptors on the cancer cell surface and will selectively kill cancer cells by irradiation.
Camel-IDS is a biotech company developing targeted radionuclide therapeutic solutions against cancer. Camel-IDS was incorporated on October 14th 2014 in Brussels, Belgium to leverage a technology platform that has been developed at VUB (Vrije Universiteit Brussel). Camel-IDS is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (Camelids), coupled with a therapeutic radioisotope. Camelids are used to transport the radioisotope to selected cancer receptors on the cancer cell surface and will selectively kill cancer cells by irradiation.
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- Burgemeester Etienne Demunterlaan 1 Brussels
- City
- Ghent
- Region
- Oost-Vlaanderen
- Postal Code
- 1090
- Country
- Belgium